多发性骨髓瘤:2018年诊断、风险分层和管理更新
该综述更新了多发性骨髓瘤的诊断标准(需≥10%克隆性骨髓浆细胞或活检证实的浆细胞瘤,加至少一项骨髓瘤定义事件)、风险分层(高危为del(17p)、t(14;16)、t(14;20);中危为t(4;14)和gain(1q);其余为标准风险)以及风险适应治疗。初始治疗为硼替佐米、来那度胺、地塞米松(VRd);高危患者可用卡非佐米、来那度胺、地塞米松(KRd)替代VRd。适合移植者接受约3–4周期初始治疗后行自体干细胞移植(ASCT),标准风险患者可在首次复发时延迟ASCT;不适合移植者接受VRd约8–12周期后用来那度胺或来那度胺加地塞米松。ASCT后标准风险患者推荐来那度胺维持,中或高危患者需以硼替佐米为基础的方案维持。复发时多需三药联合方案,选择随每次复发而异;侵袭性复发伴髓外浆细胞瘤或浆细胞白血病可能需含蒽环类联合化疗方案。
要点
- 诊断需≥10%克隆性骨髓浆细胞或活检证实的浆细胞瘤,加至少一项骨髓瘤定义事件。
- 高危为del(17p)、t(14;16)、t(14;20);中危为t(4;14)和gain(1q);其余为标准风险。
- 适合移植者初始VRd约3–4周期后行ASCT;高危患者KRd可替代VRd。
核心结论
- 多发性骨髓瘤的诊断、风险分层和治疗需根据疾病定义事件、遗传学风险及移植适宜性进行分层管理。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 多发性骨髓瘤约占血液系统恶性肿瘤的10%。
- 诊断需≥10%克隆性骨髓浆细胞或活检证实的浆细胞瘤,加一项或多项骨髓瘤定义事件:CRAB(高钙血症、肾功能衰竭、贫血或溶骨性骨病变)特征认为与浆细胞疾病相关、骨髓克隆性浆细胞≥60%、血清受累/未受累游离轻链(FLC)比值≥100(且受累FLC≥100 mg/L)、或磁共振成像上>1个局灶性病变。
- del(17p)、t(14;16)、t(14;20)患者为高危多发性骨髓瘤;t(4;14)易位和gain(1q)患者为中危;其余均为标准风险。
关键数值与推荐
- 初始治疗由硼替佐米、来那度胺、地塞米松(VRd)组成。
- 高危患者中,卡非佐米、来那度胺、地塞米松(KRd)是VRd的替代方案。
- 适合移植的患者初始治疗约3–4周期后行自体干细胞移植(ASCT);标准风险患者可在首次复发时选择延迟ASCT。
- 不适合移植的患者接受VRd约8–12周期,随后用来那度胺或来那度胺加地塞米松。
- ASCT后,标准风险患者推荐来那度胺维持;中或高危疾病患者需以硼替佐米为基础的方案维持。
临床怎么用
- 诊断时需评估克隆性骨髓浆细胞比例、CRAB特征、骨髓瘤定义事件及FLC比值。
- 根据del(17p)、t(14;16)、t(14;20)、t(4;14)和gain(1q)进行风险分层。
- 适合移植者初始VRd约3–4周期后行ASCT;高危患者KRd可替代VRd。
- 不适合移植者VRd约8–12周期后用来那度胺或来那度胺加地塞米松。
- ASCT后标准风险患者来那度胺维持;中或高危患者以硼替佐米为基础的方案维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging. RISK STRATIFICATION: Patients with del(17p), t(14;16), and t(14;20) have high-risk multiple myeloma. Patients with t(4;14) translocation and gain(1q) have intermediate-risk. All others are considered standard-risk. RISK-ADAPTED INITIAL THERAPY: Initial treatment consists of bortezomib, lenalidomide, dexamethasone (VRd). In high-risk patients, carfilzomib, lenalidomide, dexamethasone (KRd) is an alternative to VRd. In eligible patients, initial therapy is given for approximately 3–4 cycles followed by autologous stem cell transplantation (ASCT). Standard risk patients can opt for delayed ASCT at first relapse. Patients not candidates for transplant are treated with VRd for approximately 8–12 cycles followed by lenalidomide or lenalidomide plus dexamethasone. MAINTENANCE THERAPY: After ASCT, lenalidomide maintenance is recommended for standard risk patients, while maintenance with a bortezomib-based regimen is needed for patients with intermediate or high-risk disease. MANAGEMENT OF REFRACTORY DISEASE: Most patients require a triplet regimen at relapse, with the choice of regimen varying with each successive relapse. Aggressive relapse with extramedullary plasmacytomas or plasma cell leukemia may require anthracycline containing combination chemotherapy regimens.
引用
- Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018. PMID: 30400719. doi:10.1002/ajh.25117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。